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The novel alkaloid, oleracimine, presented remarkable anti-inflammatory bioactivity, and therefore, its 
pharmacokinetics was investigated in rat plasma after intravenous and oral administration by using a 
rapid ultra-high-performance liquid chromatography (UHPLC) method with UV detection at 270 nm. The 
analysis was performed on a shim-pack ODS column (75 mm×2 mm, 1.6 µm particle size, Shimadzu, 
Japan) column using isocratic elution with a mobile phase consisting of methanol-water (62:38, v/v) 
within 3 min. The results indicated that oleracimine was rapidly distributed with Tmax for 11.7 min after 
oral administration, which presented the double-peak phenomenon in the pharmacokinetic profile with 
a higher oral absolute bioavailability of 55.1% ± 7.83%.
Keywords: Portulaca oleracea L./Oleracimine. Ultra-High-Performance Liquid Chromatography/Rat 
plasma. Pharmacokinetics.
INTRODUCTION
Portulaca oleracea L . ,  a member of family 
Portulacaceae, is a warm climate, annual, green herb, 
with branched and succulent stems. As a widespread 
and abundant plant in the world, P. oleracea L. is used 
as a folk medicine in many countries. P. oleracea L. 
is a well-known traditional Chinese medicine and 
used as a treatment for removing heat, counteracting 
toxicity, cooling blood, hemostasia, and antidysentery 
(Pharmacopoeia of PRC, 2015). Previous studies reported 
that P. oleracea L. presented many pharmacological 
properties, such as antioxidant (Chen et al., 2012), 
anti-inflammatory and analgesic (Chan et al., 2000), 
hypocholesterolemic (Movahedian, Ghannadi, Vashirnia, 
2007), neuroprotective effects (Abdel Moneim, 2013), 
and antitumor (Zhao et al., 2013). Until now, the active 
compounds including terpenes (Xin et al., 2008), phenolic 
acids and coumarins (Cheng et al., 2012), flavonoids 
(Xu, Yu, Chen, 2006), and alkaloids (Jiao et al., 2015) 
were isolated from P. oleracea L., where the alkaloid has 
attracted many scholars’ attention because of its stronger 
bioactivity among natural products. Recently, five novel 
alkaloids, namely, oleracone, oleracone A, oleracimine, 
oleracimine A, and oleraciamide C have been isolated 
from P. oleracea L. in our laboratory, among which 
oleracimine presented remarkable anti-inflammatory 
effects on lipopolysaccharide-stimulated macrophages 
(Meng et al., 2016; Li et al., 2016; Xu et al., 2016). The 
results of enzyme-linked immunosorbent assay, Western 
blot, and real-time polymerase chain reaction showed that 
oleracimine remarkably inhibited nitric oxide production 
and could decrease the secretions of interleukin 6, tumor 
necrosis factor α, nitric oxide, and prostaglandin E2 
in cell culture supernatants, as well as the mRNA of 
cyclooxygenase-2 and inducible nitric oxide synthase. 
Therefore, the pharmacokinetic profile of oleracimine 
is to be investigated by a rapid and specific ultra-high-
performance liquid chromatography (UHPLC) in rat 
plasma after intravenous and oral administrations, and the 
absolute bioavailability of oleracimine was also discussed.
MATERIAL AND METHODS
Material and reagents
The whole herbs of P. oleracea L. were collected in 
Shijiazhuang (Hebei, China) in June 2014. The plant was 
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identified by Prof. Xixiang Ying. A voucher specimen 
(no. 20140312) was deposited at the School of Pharmacy, 
Liaoning University of Traditional Chinese Medicine. 
Oleracimine was isolated and purified in our laboratory 
(Li et al., 2017). For the internal standard (IS), bergapten 
was provided by Sichuan Weikeqi Biological Technology 
Co., Ltd (Chengdu, China) (Figure 1). Methanol and 
acetonitrile were all of HPLC grade provided by Damao 
Chemical Reagent Plant (Tianjin, China). All other 
reagents were of analytical grade and were purchased from 
Jinfeng Chemical Factory (Tianjin, China). Water was 
purified using Milli-Q® Biocel Ultrapure Water System 
(Millipore, Bedford, MA).
Chromatographic system and conditions
A Shimadzu UHPLC system (Japan) was equipped 
with a Solvent Delivery Pump (Shimadzu LC-30AD), 
a vacuum degasser (DGU-20A) a Shimadzu UV-VIS 
spectrophotometric detector (SPD-20A), and ChemStation 
software (Shimadzu). The analytical column was a shim-
pack ODS column (75 mm × 2 mm; 1.6-µm particle size; 
Shimadzu, Japan). The mobile phase for UHPLC analysis 
consisting of methanol–water (62:38, v/v) were passed under 
vacuum through a 0.22-μm filter membrane and degassed 
by exposure to ultrasonic waves before use. UHPLC 
analysis with UV detection at 270 nm was performed at a 
flow rate of 0.3 mL/min, and the column temperature was 
45°C. The sample injection volume was 3 µL.
Preparation of calibration standards and quality 
control (QC) samples
The stock solutions and IS were prepared by 
dissolving in methanol to yield concentrations of 144 µg/
mL and 192 µg/mL respectively. The stock solution of 
IS was diluted with methanol to 3.84 µg/mL before use. 
Working standard solutions were freshly prepared by 
mixing and diluting the above mentioned stock solution 
with methanol at appropriate ratios to yield concentrations 
of 100.0, 16.0, 8.0, 4.0, 2.0, 1.0, 0.5, and 0.25 µg/mL of 
oleracimine. The stock solution and working standard 
solutions were stored in a refrigerator. QC samples 
prepared at 0.75, 7.5, and 75.0 µg/mL of oleracimine in 
bulk and aliquots were stored frozen before use.
Animals and blood sampling
Male Wistar rats (250 ± 20 g) were supplied by the 
Laboratory Animal Service Center of Dalian Medical 
University. They were kept in an environmentally 
controlled breeding room for 1 week before the 
experiments and were fed with regular chow with standard 
laboratory food and water ad libitum and fasted overnight 
before the experiment. All animal studies were performed 
according to the requirement of the National Act on the 
Use of Experimental Animal (China) that was approved 
by the Committee of Ethics of Animal Experimentation 
of Liaoning University of Traditional Chinese Medicine.
For the pharmacokinetics, the two groups of rat 
(five rats per group) were assigned to receive oleracimine 
solution via intravenous and oral administrations at a single 
dose of 2.5 mg/kg, respectively. Serial blood samples 
(0.3 mL) were obtained via the orbitalis vena at intervals of 
2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240 min after 
administration and were collected in heparinized centrifuge 
tubes. The blood samples were immediately centrifuged at 
3,500 g for 15 min at room temperature. The plasma sample 
was stored at -20°C until analysis.
Plasma sample preparation
A 100-µL plasma, 20-µL IS (3.84 µg/mL), and 0.5-
mL acetonitrile were added, followed by vortex mixing for 
1 min and centrifuged at 3,500 g for 15 min to precipitate 
the protein. The supernatant was collected and evaporated 
to dryness at 40 °C under a gentle stream of nitrogen. The 
residue was reconstituted with 50 µL mobile phase, and 
centrifuged at 16,350 g for 5 min, and an aliquot (3 µL) 
of the supernatant was injected into the UHPLC system. 
Method validation
Selectivity
The selectivity was determined by comparing 
chromatograms of blank plasma obtained from the rats 
before dosing with the corresponding standard plasma 
spiked with the compound and IS and samples from rats 
after administration of the compound.
Linearity, LOD, and LOQ 
The linearity was evaluated over the concentration 
FIGURE 1 - Structures of internal standard (1) and olera-
cimine (2).
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range of 0.05 to 20 μg/mL at eight levels of the compound. 
The peak area ratios of the analyte with IS were plotted 
against the standard concentrations to establish calibration 
curves for oleracimine. The regression equation was 
obtained by using the 1/X2 weighted least squares linear 
regression method. The LOD and LOQ were determined by 
stepwise dilution of the QC sample at a low concentration 
level, using a signal-noise ratio of 3 and 10, respectively, 
which gives an acceptable accuracy (RE) within ± 20% 
and a precision (RSD) that did not exceed 20%.
Precision and accuracy
The intraday and interday precisions and accuracy 
were, respectively, determined within 1 day and for 
three consecutive days by analyzing the QC samples at 
low, medium, and high concentrations. The intraday and 
interday precisions were defined as the relative standard 
deviation (RSD), and accuracy was determined by 
calculating the relative error (RE).
Extraction recovery
The RSD of each concentration was calculated to 
determine the precision of the method. The extraction 
recovery was determined in sets of five replicates of the 
QC samples by comparing the peak areas obtained for 
the QC samples at low, medium, and high concentrations, 
which were subjected to an extraction procedure with 
those obtained from blank plasma extracts that were spiked 
postextraction with the corresponding concentrations.
Stability
The stabilities were carried out by the QC samples 
at low, medium, and high concentrations. Short- and long-
term stabilities were determined by analyzing the QC 
samples kept at ambient temperature (25 °C) for 4 h and 
stored at -20 °C for 1 month, respectively. Freeze–thaw 
stability was investigated after three freeze–thaw (-20 °C 
to room temperature) cycles. Then, the samples were 
processed and analyzed. The concentrations obtained were 
compared with the nominal values of the QC samples.
Pharmacokinetic study
Plasma data were subjected to analysis using both 
the statistical moment principle and the pharmacokinetic 
program, Version 1.0 (3p97) of the Chinese Society 
of Mathematical Pharmacology (Beijing, China). The 
maximum plasma concentration (Cmax) and the time 
to reach the maximum plasma concentration (Tmax) 
were obtained from 3p97 pharmacokinetic program. 
The compartmental parameters were generated by the 
pharmacokinetic program, including α half-life (t1/2α), 
β half-life(t1/2β), clearance rate (CL), and the area under 
the plasma concentration-time curve (AUC). The 
noncompartmental parameters and the area under the 
plasma concentration time curve (AUC0-t) were calculated 
using the statistical moment method. The total area under 
the plasma concentration–time curve from time zero to 
time infinity (AUC0-∞) was calculated as the sum of AUC0-t 
and Clast/K, where Clast represents the last quantifiable 
concentration, and K represents the terminal phase rate 
constant. The terminal half-life (t1/2) was calculated as 
0.693/K, and the K was estimated by natural logarithms 
of linear regression on the last five points. Clearance (CL) 
after dosing was calculated as dose/AUC0-∞. The mean 
retention time (MRT) was calculated though AUMC/AUC. 
The absolute bioavailability (%F) was calculated using the 
following formula:
Bioavailability (%F) = AUC0-∞(p.o.) × Dose (i.v.)/AUC0-∞(i.v.) 
× Dose (p.o.)
RESULTS AND DISCUSSION 
Method development and optimization
During method development, the mobile phase 
composition varied using different combinations of 
methanol, acetonitrile, and water. Here, the mobile phase 
of methanol–water (62:38, v/v) was chosen to achieve good 
peak shape, satisfactory resolution, and relatively short 
analysis time. The UV absorption spectra of oleracimine 
have a maximum absorption at 270 nm and that of IS at 
254 nm. The interferences from endogenous substances 
in the plasma were observed when the wavelength was set 
at 254 nm. Therefore, the detection wavelength was set 
at 270 nm because no interference appeared, and it was 
found to be suitable for the analysis of oleracimine and 
IS. To improve the accuracy of the method and reduce the 
error during injection process, the internal standard (IS) 
was chosen to analyze oleracimine. Baicalein, bergapten, 
kaempferol, and chrysophanol were, respectively, 
selected as candidates of IS, and only bergapten and 
chrysophanol had the close retention time with analyte, 
whereas chrysophanol presented a low recovery ratio 
which may be reduced by a high protein binding ratio of 
85.7% (Feng et al., 2013), bergapten was therefore chosen 
as the internal standard. To simultaneously acquire high 
extraction recovery of analytes and IS, several solvents, 
including acetonitrile, methanol, and their different ratios, 
were applied to precipitate protein, only the satisfactory 
recoveries of analytes and IS (81.9% and 86.3%) can be 
obtained simultaneously after acetonitrile was applied. 
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Method validation
The representative chromatograms of blank plasma, 
plasma samples spiked with analyte and IS, and a plasma 
sample obtained from a rat after the intravenous and oral 
administration of oleracimine (2.5 mg/kg) are shown 
in Figure 2, indicating a good baseline resolution of IS 
and analyte at retention times of approximately 2.4 min 
and 2.7 min, respectively. The total run time per sample 
was no more than 3 min, and there were no interfering 
peaks of endogenous compounds in the chromatographic 
determinations. The regression equation of the calibration 
curves was typically: y=0.936633x+0.00443, and the 
linear ranges for plasma were within 0.05 to 20 μg/mL 
with r> 0.9934. The LOD (S/N > 3) and the LOQ (S/N > 
10) were, respectively, 0.017 and 0.05 μg/mL in plasma. 
The RSDs of precision and the REs of accuracy at low, 
medium, and high concentrations (0.15, 1.50, 15.0 μg/mL) 
were listed in Table Ⅰ, and the results conform with the 
criteria for the analysis of biological sample according to 
the guidelines of USFDA (FDA, 2001). Mean extraction 
recovery at three concentration levels for oleracimine was 
80.6 ± 4.3% with an RSD of 8.5%, suggesting negligible 
loss during extraction. The short-, long-term, and freeze-
thaw stability of analytes in plasma ranged from 80.1% to 
83.4%, indicating that no remarkable degradation occurred 
during chromatography, extraction, and storage processes 
for the plasma samples. 
Pharmacokinetics
The pharmacokinetic parameters were estimated 
by compartmental and noncompartmental analyses, and 
all the pharmacokinetic parameters are given in Table 
Ⅱ. According to the AIC and R2, a two-compartment 
open model (weight = 1) gave the best fit to the plasma 
concentration–time curves obtained in rats. The mean 
plasma concentration-time curves of oleracimine in rat 
after oral and intravenous administrations at a dose of 
2.5 mg/kg are shown in Figure 3, which showed that 
the concentration–time curves of oleracimine presented 
the double-peak phenomenon in the pharmacokinetic 
profile, and two mechanisms should be responsible for 
the phenomenon: (1) enterohepatic recycling, the cycle 
in which bile salts and drugs excreted by the liver are 
absorbed by the intestinal mucosa and returned to the 
liver via the portal circulation (Zhu et al., 2010). 2) For 
absorption difference, the lipophilic drug was rapidly 
distributed into the organs at first and was released to the 
plasma again after the metabolism of the drug has reached 
FIGURE 2 - (A) - Representative chromatogram of blank plasma. (B) - Representative chromatogram of plasma sample 20 min 
after the intravenous administration. (C) - Representative chromatogram of oral administration of oleracimine at a dose of 
2.5 mg/kg. (D) - Representative chromatogram of plasma spiked with oleracimine and IS. Peak 1: Internal standard; Peak 2: 
oleracimine.
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a certain degree, resulting in the appearance of double 
peaks (Ma, Sun, 1993). Also, oleracimine was rapidly 
distributed and eliminated in rat plasma with a Tmax of 
11.7 min and a T1/2 of 75.2 min after oral administration. 
AUC0→∞ was 76.2 ± 6.2 μg·min/mL intravenous route is 
larger than 38.9 ± 3.1 μg·min/mL oral route, suggesting 
that the intravenous route had higher absorption than 
oral route. Besides the apparent volumes of distribution 
after both administrations (intravenous: Vd = 1.09 ± 0.20 
L/kg, oral: Vd = 2.08 ± 0.30 L/kg) were very small, 
showing that oleracimine distributed mainly in plasma. 
The CL of the intravenous route (9.8 ± 0.8 mL/min·kg) 
was smaller than that of the oral route (19.3 ± 1.4 mL/
min·kg), indicating that oleracimine after intravenous 
administration eliminated slower in the blood than 
the oral administration, and oral administration would 
be better for the metabolic process of oleracimine 
in the body. In addition, oleracimine has a higher 
oral bioavailability of 55.1 ± 7.83, suggesting that 
oleracimine is of significance for the pharmaceutical 
industry because of its anti-inflammatory bioactivity and 
higher bioavailability.
CONCLUSIONS
The pharmacokinetics of the novel alkaloid, 
oleracimine was investigated after intravenous and oral 
administrations using a rapid and specific UHPLC method 
for the first time. Oleracimine presented the double-peak 
phenomenon in the pharmacokinetic profile and a higher 
oral absolute bioavailability. Taken together, our study 
will provide reliable scientific data for its application as 
the leading compound to treat inflammatory diseases in 
clinical therapeutic approach in the future.
TABLE I - Precisions and accuracies of oleracimine in rat plasma (intra-day: n = 5; inter-day: n = 3 days with 5 replicates per day)
Added conc.
(µg/mL)
Intra-day Inter-day
Conc.
(µg/mL) 
(mean ± SD)
R.S.D. 
(%)
R.E. 
(%)
Conc.
(µg/mL) 
(mean ± SD)
R.S.D. 
(%) R.E. (%)
0.15 0.154±0.013 8.70 2.4 0.146±0.024 9.90 -2.7
1.5 1.49±0.061 4.07 -0.60 1.37±0.093 7.89 -8.7
15 14.9±0.32 2.15 -0.80 14.5±0.57 4.56 -3.3
TABLE II - Pharmacokinetic parameters of oleracimine in rat 
(mean ± S.D., n = 5) following oral and intravenous routes of 
administration at dose of 2.5 mg/kg
Parameter Intravenous route (n=5)
Oral route 
(n=5)
Camax(µg/mL) – 0.346 ± 0.013
Tamax (min) – 11.7 ± 0.86
ta1/2α (min) 2.62 ± 0.15 4.68 ± 0.21
ta1/2β (min) 65.4 ± 4.7 106 ± 5.7
tb1/2 (min) 77.4 ± 6.1 75.2 ± 4.6
bVd (L/kg) 1.09 ± 0.20 2.08 ± 0.30
k (1/min) 0.009 ± 0.001 0.009 ± 0.0006
AUCa (min·µg/mL) 75.6 ± 5.2 45.1 ± 3.8
AUCb (min·µg/mL) 76.2 ± 6.2 38.9 ± 3.1
CLb (mL/min·kg) 9.8 ± 0.8 19.3 ± 1.4
MRT (min) 111 ± 12 108 ± 8.2
Fb (%) – 55.1 ± 7.83
a,b The compartmental and non-compartmental approach, 
respectively.
FIGURE 3 - Mean plasma concentration–time curves of 
oleracimine in rats (mean ± S.D., n = 5) after the intravenous 
and oral administrations at a dose of 2.5 mg·kg-1. These 
sampling points, which could not be detected, that is, plasma 
concentrations under the LOQ, were not included in the mean 
plasma concentration–time curves.
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